Plain-English translation of NCT06935188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether dalpicilib, a new oral medication, can work better when combined with (an existing intravenous cancer drug) compared to alone. The study focuses on people with advanced head and neck cancer that has come back after surgery or spread to other parts of the body, and whose cancer did not respond to immunotherapy treatments. Researchers want to know if adding this new medication to the existing treatment helps people live longer and feel better.
Some patients with advanced head and neck cancer stop responding to standard immunotherapy treatments, leaving them with limited options. This medication is being tested to see whether it can help these patients by working alongside in a new way.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either plus the new oral medication, or alone. The is given intravenously (through an IV) either every 2 weeks or weekly, depending on the dosing schedule chosen. The new medication is taken by mouth once daily for 21 days, then you have a 7-day break, with each 28-day cycle repeating until your doctor determines the treatment should stop. You will have regular visits to check how you are responding to treatment and to monitor for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China